ASND250117C130000
- 9.80
- -0.25-2.49%
Ascendis Pharma A/S Newsroom
This Coca-Cola Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Ascendis Pharma Initiated at Buy by UBS
Ascendis Pharma Analyst Ratings
UBS Initiates Ascendis Pharma A/S(ASND.US) With Buy Rating, Announces Target Price $196
BofA Securities Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $203
Ascendis Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading
Ascendis Pharma A/S' (NASDAQ:ASND) Popularity With Investors Is Under Threat From Overpricing
Evercore Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $220
Ascendis Pharma's YORVIPATH Now Commercially Available In The U.S. For The Treatment Of Hypoparathyroidism In Adults
Jefferies Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $194
A Quick Look at Today's Ratings for Ascendis Pharma A/S(ASND.US), With a Forecast Between $167 to $211
Express News | Ascendis Pharma A/S : Jefferies Raises Target Price to $194 From $191
Ascendis Pharma (ASND) Gets a Buy From Stifel Nicolaus
Ascendis Pharma Presents New InsiGHTS Trial Of TransCon HGH In Turner Syndrome Achieved Primary Objective At Week 26; Results For All Three TransCon HGH Starting Dose Cohorts, In First Clinical Trial Of An Indication Outside Of Growth Hormone...
Ascensis Pharma Says FDA Will Review Application for Adult Treatment of Growth Hormone Deficiency
Express News | Ascendis Pharma Announces FDA Accepts Co's Supplemental Biologics License Application For TransCon HGH For The Treatment Of Adults With Growth Hormone Deficiency
European Equities Traded in the US as American Depositary Edge Higher in Wednesday Trading
Orsini Chosen by Ascendis to Distribute Treatment for Rare Endocrine Disorder in the U.S.
Peering Into Ascendis Pharma's Recent Short Interest